In:
PLOS ONE, Public Library of Science (PLoS), Vol. 16, No. 6 ( 2021-6-17), p. e0253265-
Abstract:
A therapeutic vaccine that induces lasting control of HIV infection could eliminate the need for lifelong adherence to antiretroviral therapy. This study investigated a therapeutic DNA vaccine delivered with a single adjuvant or a novel combination of adjuvants to augment T cell immunity in the blood and gut-associated lymphoid tissue in SIV-infected rhesus macaques. Animals that received DNA vaccines expressing SIV proteins, combined with plasmids expressing adjuvants designed to increase peripheral and mucosal T cell responses, including the catalytic subunit of the E . coli heat-labile enterotoxin, IL-12, IL-33, retinaldehyde dehydrogenase 2, soluble PD-1 and soluble CD80, were compared to mock-vaccinated controls. Following treatment interruption, macaques exhibited variable levels of viral rebound, with four animals from the vaccinated groups and one animal from the control group controlling virus at median levels of 10 3 RNA copies/ml or lower (controllers) and nine animals, among all groups, exhibiting immediate viral rebound and median viral loads greater than 10 3 RNA copies/ml (non-controllers). Although there was no significant difference between the vaccinated and control groups in protection from viral rebound, the variable virological outcomes during treatment interruption enabled an examination of immune correlates of viral replication in controllers versus non-controllers regardless of vaccination status. Lower viral burden in controllers correlated with increased polyfunctional SIV-specific CD8 + T cells in mesenteric lymph nodes and blood prior to and during treatment interruption. Notably, higher frequencies of colonic CD4 + T cells and lower Th17/Treg ratios prior to infection in controllers correlated with improved responses to ART and control of viral rebound. These results indicate that mucosal immune responses, present prior to infection, can influence efficacy of antiretroviral therapy and the outcome of immunotherapeutic vaccination, suggesting that therapies capable of modulating host mucosal responses may be needed to achieve HIV cure.
Type of Medium:
Online Resource
ISSN:
1932-6203
DOI:
10.1371/journal.pone.0253265
DOI:
10.1371/journal.pone.0253265.g001
DOI:
10.1371/journal.pone.0253265.g002
DOI:
10.1371/journal.pone.0253265.g003
DOI:
10.1371/journal.pone.0253265.g004
DOI:
10.1371/journal.pone.0253265.g005
DOI:
10.1371/journal.pone.0253265.g006
DOI:
10.1371/journal.pone.0253265.g007
DOI:
10.1371/journal.pone.0253265.s001
DOI:
10.1371/journal.pone.0253265.s002
DOI:
10.1371/journal.pone.0253265.s003
DOI:
10.1371/journal.pone.0253265.s004
DOI:
10.1371/journal.pone.0253265.s005
DOI:
10.1371/journal.pone.0253265.s006
DOI:
10.1371/journal.pone.0253265.s007
DOI:
10.1371/journal.pone.0253265.s008
DOI:
10.1371/journal.pone.0253265.s009
DOI:
10.1371/journal.pone.0253265.s010
DOI:
10.1371/journal.pone.0253265.s011
DOI:
10.1371/journal.pone.0253265.s012
DOI:
10.1371/journal.pone.0253265.s013
DOI:
10.1371/journal.pone.0253265.s014
DOI:
10.1371/journal.pone.0253265.s015
DOI:
10.1371/journal.pone.0253265.s016
DOI:
10.1371/journal.pone.0253265.s017
DOI:
10.1371/journal.pone.0253265.r001
DOI:
10.1371/journal.pone.0253265.r002
DOI:
10.1371/journal.pone.0253265.r003
DOI:
10.1371/journal.pone.0253265.r004
DOI:
10.1371/journal.pone.0253265.r005
DOI:
10.1371/journal.pone.0253265.r006
Language:
English
Publisher:
Public Library of Science (PLoS)
Publication Date:
2021
detail.hit.zdb_id:
2267670-3
Permalink